BDSX Biodesix, Inc.
Stock · NasdaqGM · United States · Healthcare · US09075X2071
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Biodesix, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
8.53 USD
-57.01%
52-week range
5.26 – 31.97
Dividend yield—
Market cap90.0M
NowoTrade score
26 Grade A
Price history
Daily prices in USD.
Updated 07 Nov 2026 09:18. Information, not advice.
Results
Next results
25 Feb 2027
in 110 days · 16:00 · estimate -0.43
Last results
-0.75 vs -0.75 estimated
05 Nov 2026 · In line -0.2%
Beat the estimate
9 of 12
2 missed · 1 in line
Average surprise
+10.4%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 25 Feb 2027 16:00 | -0.43 | — | — | Upcoming |
| 05 Nov 2026 16:00 | -0.75 | -0.75 | -0.2% | In line |
| 05 Aug 2026 16:00 | -0.90 | -0.71 | +21.4% | Beat |
| 04 May 2026 16:00 | -1.10 | -0.81 | +26.1% | Beat |
| 26 Feb 2026 16:00 | -0.87 | -0.49 | +43.4% | Beat |
| 03 Nov 2025 16:00 | -1.51 | -1.16 | +23.0% | Beat |
| 07 Aug 2025 16:00 | -1.37 | -1.60 | -17.1% | Miss |
| 13 May 2025 16:00 | -1.40 | -1.60 | -14.3% | Miss |
| 03 Mar 2025 16:00 | -1.33 | -1.20 | +10.0% | Beat |
| 01 Nov 2024 06:00 | -1.52 | -1.40 | +7.9% | Beat |
| 07 Aug 2024 16:00 | -1.84 | -1.60 | +13.0% | Beat |
| 08 May 2024 16:00 | -2.87 | -2.80 | +2.3% | Beat |
| 01 Mar 2024 06:00 | -2.20 | -2.00 | +9.1% | Beat |
| 07 Nov 2023 16:00 | -3.00 | -2.80 | +6.7% | Beat |
| 07 Aug 2023 16:00 | -4.13 | -3.40 | +17.7% | Beat |
| 11 May 2023 16:00 | -4.73 | -4.80 | -1.4% | Miss |
| 06 Mar 2023 06:00 | -5.55 | -7.00 | -26.1% | Miss |
| 03 Nov 2022 06:00 | -6.55 | -6.80 | -3.8% | Miss |
| 04 Aug 2022 06:00 | -9.30 | -8.00 | +14.0% | Beat |
| 11 May 2022 06:00 | -8.50 | -10.00 | -17.7% | Miss |
| 14 Mar 2022 06:00 | -9.85 | -9.80 | +0.5% | In line |
| 15 Nov 2021 07:00 | -9.55 | -8.20 | +14.1% | Beat |
| 10 Aug 2021 16:00 | -5.80 | -8.20 | -41.4% | Miss |
| 11 May 2021 16:00 | -3.50 | -5.20 | -48.6% | Miss |
| 16 Mar 2021 15:00 | -10.00 | -5.07 | +49.3% | Beat |
| 10 Dec 2020 16:00 | -5.00 | -6.60 | -32.0% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 88.5M | +24.1% | -35.3M | -39.8% | -4.67 | +29.2% | -23.7M |
| 2024 | 71.3M | +45.3% | -42.9M | -60.2% | -6.60 | +48.4% | -52.1M |
| 2023 | 49.1M | +28.5% | -52.1M | -106.2% | -12.80 | +58.7% | -45.9M |
| 2022 | 38.2M | — | -65.4M | -171.3% | -31.00 | — | -48.5M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 06 Nov 2026 | 12.42 | 13.04 | 7.96 | 8.53 | -57.01% | 1,586,800 | |
| 05 Nov 2026 | 21.30 | 21.30 | 19.07 | 19.84 | -7.68% | 185,600 | |
| 04 Nov 2026 | 21.56 | 22.23 | 20.42 | 21.49 | +2.09% | 148,000 | |
| 03 Nov 2026 | 21.80 | 22.89 | 20.74 | 21.05 | -3.35% | 38,800 | |
| 02 Nov 2026 | 23.24 | 23.31 | 21.37 | 21.78 | -6.34% | 75,600 | |
| 30 Oct 2026 | 25.06 | 25.06 | 22.70 | 23.25 | -5.93% | 67,100 | |
| 29 Oct 2026 | 22.94 | 24.87 | 22.94 | 24.72 | +8.14% | 70,100 | |
| 28 Oct 2026 | 21.87 | 22.98 | 21.27 | 22.86 | +4.15% | 101,300 | |
| 27 Oct 2026 | 21.41 | 22.43 | 20.11 | 21.95 | +3.25% | 141,700 | |
| 26 Oct 2026 | 21.54 | 22.36 | 21.02 | 21.26 | +0.38% | 60,900 | |
| 23 Oct 2026 | 23.66 | 23.70 | 21.11 | 21.18 | -11.53% | 139,600 | |
| 22 Oct 2026 | 23.76 | 24.99 | 23.38 | 23.94 | +0.04% | 138,800 | |
| 21 Oct 2026 | 24.07 | 24.55 | 23.66 | 23.93 | +0.25% | 54,200 | |
| 20 Oct 2026 | 23.50 | 24.92 | 23.50 | 23.87 | +2.01% | 49,300 | |
| 19 Oct 2026 | 23.68 | 25.24 | 23.04 | 23.40 | -1.10% | 55,400 | |
| 16 Oct 2026 | 24.79 | 24.79 | 22.60 | 23.66 | -4.25% | 79,600 | |
| 15 Oct 2026 | 23.92 | 24.77 | 23.84 | 24.71 | +3.00% | 35,200 | |
| 14 Oct 2026 | 24.92 | 25.08 | 23.65 | 23.99 | -4.04% | 80,900 | |
| 13 Oct 2026 | 25.79 | 25.79 | 24.80 | 25.00 | -2.72% | 53,300 | |
| 12 Oct 2026 | 26.02 | 26.62 | 25.19 | 25.70 | -1.23% | 41,000 | |
| 09 Oct 2026 | 25.68 | 26.64 | 25.63 | 26.02 | +1.52% | 46,700 | |
| 08 Oct 2026 | 26.24 | 26.50 | 25.10 | 25.63 | -2.99% | 96,000 | |
| 07 Oct 2026 | 27.50 | 27.78 | 26.07 | 26.42 | -5.51% | 57,600 | |
| 06 Oct 2026 | 29.30 | 29.99 | 27.52 | 27.96 | -3.79% | 102,200 | |
| 05 Oct 2026 | 27.72 | 30.00 | 26.53 | 29.06 | +4.83% | 181,200 |
Page 1 of 51
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Biodesix (BDSX) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 06 Nov 2026 15:31
- Champions Oncology vs. Biodesix: Which Oncology Stock Is a Better Buy? (opens in a new tab) Zacks · 06 Nov 2026 15:16
- Biodesix Inc (BDSX) (Q3 2026) Earnings Call Highlights: Revenue Growth Offset by Sales Force ... (opens in a new tab) GuruFocus.com · 06 Nov 2026 05:27
- Biodesix Stock Crashes Nearly 30% After Q3 Revenue Miss, Slashes 2026 Outlook (opens in a new tab) Benzinga · 06 Nov 2026 04:24
- Biodesix, Inc. (BDSX) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 06 Nov 2026 03:14
- What Biodesix (BDSX) Said on Its Q3 Earnings Call (opens in a new tab) MarketBeat · 05 Nov 2026 23:14
- Biodesix, Inc. (BDSX) Reports Q3 Loss, Lags Revenue Estimates (opens in a new tab) Zacks · 05 Nov 2026 21:45
- Biodesix Announces Third Quarter 2026 Results and Highlights (opens in a new tab) 05 Nov 2026 21:01
- Biodesix Q3 2026 Earnings Call Transcript (opens in a new tab) Benzinga · 05 Nov 2026 18:35
- Biodesix Lowers FY2026 Sales Guidance from $108.000M-$114.000M to $101.000M-$103.000M vs $111.817M Est (opens in a new tab) Benzinga · 05 Nov 2026 17:03
- Biodesix to Participate in Upcoming Investor Conferences (opens in a new tab) 04 Nov 2026 11:00
- All You Need to Know About Biodesix (BDSX) Rating Upgrade to Buy (opens in a new tab) Zacks · 29 Oct 2026 15:00
- Will Biodesix, Inc. (BDSX) Report Negative Earnings Next Week? What You Should Know (opens in a new tab) Zacks · 29 Oct 2026 13:00
- Biodesix (BDSX) Stock Sees Fair Value Lift As Analysts Back MRD Growth (opens in a new tab) Simply Wall St. · 15 Oct 2026 02:15
- Will Thermo Fisher’s New cGMP CHO-K1 Panel and MRD Moves Change Thermo Fisher Scientific's (TMO) Narrative (opens in a new tab) Simply Wall St. · 29 Sep 2026 02:09
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 19.84 USD
- Market cap
- 90.0M
- Exchange
- NasdaqGM
- Country
- United States
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 0.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 7.5 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 50: three or more warnings
- Thin interest cover: operating profit is only -3.6× the interest
- The last full year was a loss
- Total debt has risen three years in a row
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 18 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -38.77× | Weak | 14.98× |
| Price / book | 9.84× | Weak | 3.94× |
| Price / sales | 0.87× | Good | 3.37× |
| EV / EBITDA | -16.74× | Weak | 12.96× |
| Free cash flow yield | -12.1% | Weak | 2.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 82.5% | Good | 59.2% |
| Operating margin | -20% | Weak | 7.4% |
| Net margin | -27% | Weak | 3.4% |
| Return on equity | -540% | Weak | 5.7% |
| Return on assets | -14.1% | Weak | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 32.3% | Good | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 7.85× | Weak | 0.46× |
| Interest cover | -3.6× | Weak | 3.26× |
| Current ratio | 2.85× | Good | 2.35× |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow BDSX and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.